跳转至内容
Merck

SML0195

Sigma-Aldrich

米法莫肽

≥98% (HPLC)

别名:

CGP-19835, MTP-PE, MTP-脑磷脂, N-(N-乙酰胞壁酰)-L-丙氨酰-D-α-谷氨酰胺基-N- [(7R)-4-羟基-4-氧化-10-氧代-7- [(1-氧代十六烷基)氧]-3,5,9-三氧-4-磷酸五氯-1-基]-L-丙氨酸酰胺, 胞壁酰三肽磷脂酰乙醇胺

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C59H109N6O19P
CAS号:
分子量:
1237.50
分類程式碼代碼:
12352200
PubChem物質ID:
NACRES:
NA.77

品質等級

化驗

≥98% (HPLC)

形狀

powder

儲存條件

desiccated

顏色

white to beige

溶解度

water: 2 mg/mL, clear (warmed)

起源

Novartis

儲存溫度

−20°C

SMILES 字串

CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCCNC(=O)[C@H](C)NC(=O)CC[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@@H]([C@H](O)[C@H](O)CO)[C@@H](NC(C)=O)C=O)C(N)=O)OC(=O)CCCCCCCCCCCCCCC

InChI

1S/C59H109N6O19P/c1-7-9-11-13-15-17-19-21-23-25-27-29-31-33-52(71)80-41-47(84-53(72)34-32-30-28-26-24-22-20-18-16-14-12-10-8-2)42-82-85(78,79)81-38-37-61-57(75)43(3)62-51(70)36-35-48(56(60)74)65-58(76)44(4)63-59(77)45(5)83-55(54(73)50(69)40-67)49(39-66)64-46(6)68/h39,43-45,47-50,54-55,67,69,73H,7-38,40-42H2,1-6H3,(H2,60,74)(H,61,75)(H,62,70)(H,63,77)(H,64,68)(H,65,76)(H,78,79)/t43-,44-,45+,47+,48+,49-,50+,54+,55+/m0/s1

InChI 密鑰

ZVLWUMPAHCEZAW-KRNLDFAISA-N

應用

Mifamurtide 可用于免疫学和癌症相关细胞信号传导研究。

生化/生理作用

Mifamurtide 是一种免疫调节剂,可调节单核细胞和巨噬细胞的活化。Mifamurtide 上调促炎细胞因子如 TNF-α 的分泌、IL-1、IL-8、一氧化氮及前列腺素 E 2 和 D 2 。在儿童和青年高级别骨肉瘤中具有抗肿瘤作用。
Mifamurtide(胞壁酰三肽磷脂酰乙醇胺;MTP-脑磷脂;MTP-PE)是一种合成的亲脂性胞壁酰二肽类似物。它作为免疫刺激剂通过体内巨噬细胞活化促进癌细胞破坏。
胞壁酰二肽的合成亲脂性类似物。免疫刺激剂通过体内巨噬细胞活化促进癌细胞破坏。抗肿瘤免疫调节剂。

特點和優勢

该化合物由 Novartis 开发。想要浏览其他由制药公司开发的化合物以及已批准药物/候选药物清单,请单击此处

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Karthik Venkatakrishnan et al.
European journal of clinical pharmacology, 68(10), 1347-1355 (2012-03-31)
This study evaluated the pharmacokinetics (PK), pharmacodynamics (PD), safety/tolerability, and cardiac safety of liposomal muramyl tripeptide phosphatidyl-ethanolamine [mifamurtide (L-MTP-PE)] in healthy adults. L-MTP-PE 4 mg was administered intravenously over 30 min. Study participants were monitored from 24 h preinfusion until 72 h postinfusion. Blood
Prospectively planned analysis of data from a phase III study of liposomal muramyltripeptide phosphatidylethanolamine in the treatment of osteosarcoma.
Jean-Loup Romet-Lemonne et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23(26), 6437-6438 (2005-09-13)
Kosei Ando et al.
Expert opinion on pharmacotherapy, 12(2), 285-292 (2011-01-14)
The standard treatment for osteosarcoma requires both macroscopic surgical wide resection and postoperative multi-drug chemotherapy in neoadjuvant and adjuvant settings. However, the 5-year event-free survival has remained at a plateau of 60-70% of patients with nonmetastatic osteosarcoma for more than
A Nardin et al.
Current cancer drug targets, 6(2), 123-133 (2006-03-15)
About one third of osteosarcoma patients develop lung metastasis refractory to chemotherapy. Recent studies indicate that biological response modifiers activating the patient's immune system may help controlling minimal residual disease via pathways distinct from those used by cytotoxic drugs, and
R M Durham et al.
The Journal of surgical research, 76(2), 179-184 (1998-08-12)
Muramlytripeptide phosphatidylethanolamine (MTP) stimulates synthesis of cytokines by hepatic Kupffer cells. We have shown in a perfused rat liver model that secondary ischemia/reperfusion (I/R) downregulates tumor necrosis factor alpha (TNF-alpha) expression after Escherichia coli (EC) bacteremia. Here, we tested the

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门